Keros Therapeutics, Inc (KROS) Fair Value & Analysis
Healthcare · US · Market cap $211M
Keros Therapeutics, Inc
KROS · US
Fair value as of: Jul 17, 2026
From 24 valuation models · updated today
Fair value updated Jul 17, 2026, revised from $68.92 to $10.19 (−85.2%) since Jun 24, 2026. Share price +5.8% over the past month.
Price vs Fair Value (12 months)
12‑month range $9.91 – $21.84 · fair‑value band $7.68 – $12.74 · the $10.61 price screens above the $10.19 fair value. As of Jul 17, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Keros Therapeutics, Inc (KROS) currently trades at $10.61, while our model-based Fair Value estimate is $10.19, implying the stock looks roughly 4.0% fairly valued today. We read business quality at 59/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).
Trailing-twelve-month revenue stands at $33.2M. It earns a return on equity of -16.8%. The balance sheet holds a net cash position of $271M. Fundamentals as of Jul 17, 2026
Our scenario range runs from $7.68 (bear case) to $12.74 (bull case); at $10.61, the current price sits within that range. The share trades about 53% below its 52-week high and 9% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -27% fair-value upside, at -4%, KROS screens cheaper than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 17, 2026. TTM = trailing twelve months.
About the company
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics to treat patients with disorders linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. It develops rinvatercept, which acts as a ligand trap and inhibits the biological effects of myostatin and activin A in Phase 1 clinical trials for Duchenne Muscular Dystrophy and Amyotrophic Lateral Sclerosis; and elritercept to target TGF-ß signaling pathways to address diseases that arise from ineffective hematopoiesis in Phase 3 clinical trials for Myelodysplastic Syndromes and Phase 2 clinical trials for Myelofibrosis. The company has collaboration and license agreements with Hansoh (Shanghai) Healthtech Co., Ltd. to develop, manufacture, and commercialize elritercept and licensed products containing elritercept; and Takeda Pharmaceuticals U.S.A., Inc. to develop, manufacture, and commercialize elritercept and certain …
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Keros Therapeutics, Inc reported revenue of $244M in FY2025 versus $20.1M in FY2021, a compound +86.7%/yr. Reported net income was $87.0M in FY2025.
Is KROS fairly valued? → Check now
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Jul 17, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX | 7,746 MXN | 449.62 MXN | -94% |
| Regeneron Pharmaceuticals, Inc REGN | $635.45 | $547.01 | -14% |
| UCB SA UCB | €251.70 | €180.06 | -28% |
| argenx SE ARGNF | $900.00 | $382.64 | -57% |
| Samsung Biologics Co 207940 | 1,000,000 KRW | 1,091,384 KRW | +9% |
| CSL Limited CSL | A$97.91 | A$100.60 | +3% |
| Celltrion, Inc 068270 | 167,300 KRW | 76,382 KRW | -54% |
| BioNTech SE B1NT34 | R$29.19 | R$21.38 | -27% |
| WuXi Biologics (Cayman) Inc 2269 | HK$32.74 | HK$24.99 | -24% |
| Innovent Biologics, Inc 1801 | HK$85.35 | HK$21.13 | -75% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Keros Therapeutics, Inc (KROS) undervalued?
What is the fair value of KROS?
What is the quality score of KROS?
What is the revenue of Keros Therapeutics, Inc (KROS)?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Tell me when Keros Therapeutics, Inc reaches its Fair Value
Just your email, and we'll notify you when the price and Fair Value of Keros Therapeutics, Inc materially change. Free bonus: the monthly Top-25 report of the most undervalued quality stocks.
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.